ArticleCancers2026

Real-World Outcomes of Nivolumab Plus Ipilimumab in Metastatic Melanoma: A Stratified Analysis of First- and Second-Line Treatment.

Alexandr Iurchenkov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.